close

Videos

  Clinical Conversations by Experts View all

Featured Videos

Leaders in Radiopharmaceuticals: Disruptive Innovations and Personal Perspectives

Treatments in Development in NMIBC

Genomic Classifier in Prostate Cancer: Intermediate-Risk

Latest Videos

Recent Physician-Scientist Review Articles

  State of the Evidence Review Articles
BERJAYA
Advanced Bladder Cancer
View all Advanced Bladder Cancer
BERJAYA
PSMA-Targeted Therapy
View all PSMA-Targeted Therapy

Transformative Evidence

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

ARANOTE

Presented by Zachary Klaassen, MD, MSc
The 2026 Southeastern Section of the AUA Annual Meeting featured a presentation by Dr. Zachary Klaassen of a post hoc analysis from the phase 3 ARANOTE trial evaluating darolutamide plus androgen-deprivation therapy (ADT) versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with outcomes stratified by disease volume.

Genomic Biomarker Testing

Presented by Pedro C. Barata, MD, MSc
The 2026 ASCO GU Annual Symposium was host to a prostate cancer poster session. Dr. Pedro Barata presented an analysis of real-world patient characteristics and treatment patterns among metastatic castration-resistant prostate cancer (mCRPC) patients treated with talazoparib + enzalutamide in the United States.

Trials in Progress

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

MEVPRO-3 Trial

Presented by Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO, discussed MEVPRO-3, a phase III trial of mevrometostat + enzalutamide versus placebo + enzalutamide in mCSPC. Enhancer of zeste homolog 2 (EZH2) enzymatic activity plays a crucial role in prostate cancer progression. Mevrometostat, an oral potent and selective EZH2 inhibitor, may synergize with androgen receptor pathway inhibitors to delay androgen receptor pathway inhibitor resistance.

MEVPRO-1 & 2 Trial

Presented by Nobuaki Matsubara, MD
The 2026 ASCO GU cancers symposium held in San Francisco, CA, was host to the Poster Session A: Prostate Cancer. Dr. Nobuaki Matsubara presented Poster 195: Efficacy and safety of mevrometostat in combination with enzalutamide in patients with mCRPC: Data from a phase 1 study.